Compare · IDXG vs RMD
IDXG vs RMD
Side-by-side comparison of Interpace Biosciences, Inc. (IDXG) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXG and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $31.49B.
- RMD has hit the wire 2 times in the past 4 weeks while IDXG has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 1 for IDXG).
- Company
- Interpace Biosciences, Inc.
- ResMed Inc.
- Price
- -
- $219.82+0.11%
- Market cap
- -
- $31.49B
- 1M return
- -
- -2.86%
- 1Y return
- -
- -6.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 25
Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IDXG
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Interpace Biosciences, Inc.
- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
- Large owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)
- Large owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Interpace Biosciences, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Interpace Biosciences, Inc.
- Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.